Roche Holding AG (ROG) - Stock Price & Dividends

Exchange: SIX Swiss Exchange • Country: Switzerland • Currency: CHF • Type: Common Stock • ISIN: CH0012032048

Pharmaceuticals, Diagnostics, Cancer, Diabetes, Covid-19

Rocher Holding AG is a global healthcare company that operates in multiple regions, including Europe, North America, Latin America, Asia, Africa, Australia, and Oceania.

The company is a leader in the pharmaceutical industry, offering a wide range of products that cater to various therapeutic areas. These include treatments for anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune disorders, neurological disorders, ophthalmology, respiratory disorders, and transplantation. Additionally, Roche is continuously developing new products to address emerging health needs.

Roche is also a pioneer in the diagnostics business, providing a comprehensive range of in vitro tests for the diagnosis of various diseases, including cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. The company's diagnostic instruments and digital health solutions enable healthcare professionals to make informed decisions and provide better patient care.

With a rich history dating back to 1896, Roche Holding AG is headquartered in Basel, Switzerland, and has established itself as a trusted name in the healthcare industry. To learn more about Roche's innovative products and services, visit their website at

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Roche Holding AG (ROG) - Stock Price & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for Roche Holding AG (ROG) - Stock Price & Dividends

ROG Stock Overview

Market Cap in USD 213,137m
Sector Healthcare
Industry Drug Manufacturers - General
GiC SubIndustry Pharmaceuticals
TER 0.00%
IPO / Inception

ROG Stock Ratings

Growth 5y -12.6
Fundamental 72.7
Dividend 6.81
Rel. Performance vs Sector -2.59
Analysts -
Fair Price Momentum 222.99 CHF
Fair Price DCF 671.77 CHF

ROG Dividends

Yield 12m 3.91%
Yield on Cost 5y 4.03%
Dividends CAGR 5y 1.77%
Payout Consistency 100.0%

ROG Growth Ratios

Growth 12m -7.41%
Growth Correlation 12m -55%
Growth Correlation 3m 33%
CAGR 5y 0.62%
CAGR/Mean DD 5y 0.04
Sharpe Ratio 12m -0.71
Alpha vs SP500 12m -20.11
Beta vs SP500 5y weekly 0.35
ValueRay RSI 93.15
Volatility GJR Garch 1y 17.74%
Price / SMA 50 7.46%
Price / SMA 200 5.76%
Current Volume 1111.3k
Average Volume 20d 1209.8k

External Links for ROG Stock

Fund Manager Positions
What is the price of ROG stocks?
As of June 18, 2024, the stock is trading at CHF 245.50 with a total of 1,111,345 shares traded.
Over the past week, the price has changed by +2.42%, over one month by +3.54%, over three months by +6.93% and over the past year by -8.63%.
What are the forecast for ROG stock price target?
According to ValueRays Forecast Model, ROG Roche Holding AG will be worth about 243.2 in June 2025. The stock is currently trading at 245.50. This means that the stock has a potential downside of -0.95%.
Issuer Forecast Upside
Wallstreet Target Price 271.4 10.6
Analysts Target Price - -
ValueRay Target Price 243.2 -0.95

A Deep Dive into Roche Holding AG: From Origins to Global Healthcare Dominance

History of Roche Holding AG

Founded in 1896 by Fritz Hoffmann-La Roche in Basel, Switzerland, Roche Holding AG has grown from a small drug laboratory into a global powerhouse in healthcare. The company began with an emphasis on producing reliable pharmaceutical products and soon became known for innovations, such as the synthesis of Vitamin C in the 1930s. Over decades, Roche has consistently invested in research and development, leading to breakthroughs in various medical fields.

Core Business

Roche’s core business focuses on pharmaceuticals and diagnostics. Its pharmaceutical division is renowned for developing innovative treatments, especially in oncology, immunology, infectious diseases, ophthalmology, and neuroscience. Meanwhile, the diagnostics division offers a wide range of testing solutions, playing a crucial role in personalized healthcare by enabling faster and more accurate diagnosis and treatment.

Side Business and Ventures

Beyond its primary operations, Roche has diversified its business by investing in genomic research and data-driven medical insights through subsidiaries such as Foundation Medicine and Flatiron Health. These ventures underscore Roche’s commitment to advancing precision medicine, leveraging big data and analytics to improve patient care.

Current Market Status

As of the latest reports, Roche Holding AG continues to be a leading player in the global healthcare market. Its commitment to innovation and significant R&D investment have ensured a robust product pipeline and sustained growth. Despite challenges such as patent expiries and market competition, Roche’s strategic acquisitions and focus on emerging fields like personalized healthcare and digital health solutions position it well for future success.